FDA says tirzepatide shortage is over after taking a second look - NBC News
Dec 19, 2024 · The Food and Drug Administration said Thursday it’s standing by its earlier decision that the shortage of tirzepatide — the active ingredient in Eli Lilly’s diabetes and …
Lilly launches lower-price weight loss drug without injector pen - CNN
Aug 27, 2024 · The U.S. Food and Drug Administration (FDA) approved Eli Lilly and Company's (NYSE: LLY) Zepbound™ (tirzepatide) injection, the first and only obesity treatment of its kind …
FDA confirms end of Eli Lilly’s tirzepatide shortage after re ...
Dec 20, 2024 · Many patients seeking glucagon-like peptide-1 receptor agonists (GLP-1RAs) turned to compound pharmacies as demand for Eli Lilly’s tirzepatide, branded as Ozempic and …
FDA approves Zepbound® (tirzepatide) as the first and only …
INDIANAPOLIS, Dec. 20, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the U.S. Food and Drug Administration (FDA) approved Zepbound ® (tirzepatide) …
Lilly commends ITC ruling cracking down on the unlawful …
Dec 23, 2024 · The ruling applies to anyone importing illicit knockoff tirzepatide products. “Most people have no idea that the knockoff compounded drugs they are taking may be coming from …
Eli Lilly's tirzepatide is off the FDA's drug shortage list: Here's ...
Oct 16, 2024 · Eli Lilly's weight-loss drug is no longer on the Food and Drug Administration's drug shortage list. Compounding pharmacies say this will limit patient access.
News Release - Eli Lilly and Company
INDIANAPOLIS, Aug. 1, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today positive topline results from the SUMMIT phase 3 clinical trial evaluating the safety and …
FDA to reconsider tirzepatide removal from shortage list - The Hill
Oct 14, 2024 · The Food and Drug Administration (FDA) said it will reconsider its decision to remove Eli Lilly’s blockbuster weight loss and diabetes drug from its official shortage list and …
Lilly says tirzepatide supply issues are resolving
2 days ago · Eli Lilly has raised its revenue guidance for 2024 by $3 billion, after reporting strong growth for tirzepatide in diabetes and obesity, fuelled by the end of supply constraints for …
FDA to Reconsider Removal of Lilly's Obesity Drug From Shortage …
Oct 15, 2024 · The FDA has agreed to review its decision to remove Eli Lilly’s LLY tirzepatide — the active ingredient used in diabetes drug Mounjaro and obesity drug Zepbound — from its …
- Some results have been removed